With existing resources concentrated on late-stage development of two lead products, Dynavax Technologies Corp. entered a $50 million financing arrangement with Symphony Capital Partners LP to support work on its second-generation programs in cancer, hepatitis B and hepatitis C. (BioWorld Today) Read More
